HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • Rx-to-OTC Switch
  • Self-Care
  • AI
  • Interviews

Health
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Beauty
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Wellness
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Podcasts

Conference Coverage

Partner Insights

HBW Insight Perspectives

Exploring key commercial, policy and market trends ahead.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
HBW Insight logo
  1. Home
  2. >>HBW Insight
  3. >>Wellness
  4. >>Business

Business

Marketing & AdvertisingEarningsDealsStrategyManufacturingStartups & SMEsRetail
  • HI-Wellness (Premium-1): Asthme et DT2 : une association qui dépasse le hasard

    HI-Wellness (Premium-1): Asthme et DT2 : une association qui dépasse le hasard

    Nov 11 2025

    Des recherches montrent que l’asthme et le diabète de type 2 (DT2) sont liés au-delà du hasard, partageant des facteurs inflammatoires et métaboliques. Cette association souligne l’importance d’une surveillance accrue et d’une prise en charge adaptée pour prévenir les complications chez les patients

  • Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

    Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

    Oct 17 2025

    Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

  • Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

    Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

    Sep 29 2025

    Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

  • Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

    Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

    Sep 25 2024 
    • By Eileen Francis

    At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”


  • Dermapharm Makes Changes To Turn Around Arkopharma’s Performance

    Dermapharm Makes Changes To Turn Around Arkopharma’s Performance

    Aug 30 2024 
    • By Tom Gallen

    Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.

  • Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

    Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

    Aug 27 2024 
    • By David Ridley

    In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

  • Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

    Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

    Aug 26 2024 
    • By Malcolm Spicer

    Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

  • ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

    ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

    Aug 25 2024 
    • By Malcolm Spicer

    Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.


  • ‘Inside Regulatory Affairs’ With Kenvue's Kevin Whelan

    ‘Inside Regulatory Affairs’ With Kenvue's Kevin Whelan

    Aug 23 2024

    This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to Kenvue's Kevin Whelan.

  • Consumer Health Launches: Viome, Liquid Core, NOW Offer Line Extensions To Chew On

    Consumer Health Launches: Viome, Liquid Core, NOW Offer Line Extensions To Chew On

    Aug 22 2024 
    • By Malcolm Spicer

    Viome Life Sciences launches VRx MyBiotics Toothpaste & Gel to complete its Oral Health Solution system; Liquid Core Gum’s Edge Performance made with its Liquid Core and Flavor Wave properties and distributed in packaging developed using sustainable cardboard tubes; and NOW Health Group launches Omega-3 Gummy Chews and E-Sport Reaction supplements.

  • Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

    Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

    Aug 20 2024 
    • By Malcolm Spicer

    David Ball moves from Bayer’s North America business to be Perrigo’s first chief brand and digital officer. He joins CEO who also moved to Perrigo from Bayer with decades of branded product experience.

  • California Legislation To Age-Restrict Sales Of Weight Loss Supplements, OTCs On Ice For 2024

    California Legislation To Age-Restrict Sales Of Weight Loss Supplements, OTCs On Ice For 2024

    Aug 16 2024 
    • By Malcolm Spicer

    California Senate Appropriations Committee suspends consideration of bill for current session after it and Judiciary Committee voted to recommend passing the bill earlier in session. Legislative sessions continue in Massachusetts and New Jersey with bills for similar restrictions.


  • US FTC’s Final Rule On Fake Consumer Reviews ‘Unlocks’ Remedies For Obtaining Civil Penalties

    US FTC’s Final Rule On Fake Consumer Reviews ‘Unlocks’ Remedies For Obtaining Civil Penalties

    Aug 16 2024 
    • By Eileen Francis

    The FTC says its final rule banning fake consumer reviews and testimonials will help to restore its depleted toolbox for obtaining civil penalties. The agency maintains the final rule’s benefits will greatly outweigh costs for honest companies increasingly set back by bad actors in the space.

  • US Wellness Market News: WishGarden 45, SoWell Launch, Vital Proteins Paper, Vitaminwater Colors

    US Wellness Market News: WishGarden 45, SoWell Launch, Vital Proteins Paper, Vitaminwater Colors

    Aug 15 2024 
    • By Malcolm Spicer

    WishGarden Herbs marks 45 years with line extensions; Obesity doctor develops SoWell supplements for GLP-1 patients; Vital Proteins makes sustainability vital in packaging; and interior decoration and rent awards in vitaminwater campaign.

  • Marketing Dietary Supplements To GLP-1 Patients On Brand For Supergut Line, Up Now For iHerb

    Marketing Dietary Supplements To GLP-1 Patients On Brand For Supergut Line, Up Now For iHerb

    Aug 14 2024 
    • By Malcolm Spicer

    Supergut brand owner Uplifting Results Labs makes Gut Healthy GLP-1 Booster prebiotic fiber mix along with its snack bars and meal-replacement shakes available through GNC. IHerb launches supplements addressing side GLP-1 effects including nausea and pain, loss of muscle mass and changing blood sugar levels.

  • Stay Tuned For FDA OTC Monographs Portal Update

    Stay Tuned For FDA OTC Monographs Portal Update

    Aug 14 2024 
    • By Malcolm Spicer

    With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.


  • Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season

    Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season

    Aug 14 2024 
    • By Tom Gallen

    OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.

  • US Consumer Health Business Results: Herbalife, Amphastar, ChromaDex

    US Consumer Health Business Results: Herbalife, Amphastar, ChromaDex

    Aug 13 2024 
    • By Malcolm Spicer

    Herbalife adds distributors and training as sales slow; Amphastar bullish on Primatene Mist $100M full-year target; and ChromaDex net sales up 12%.

  • US Consumer Heath Market News: Trillium Sold, CRN Speakers, AG1 CEO, ChromaDex Counsel, More

    US Consumer Heath Market News: Trillium Sold, CRN Speakers, AG1 CEO, ChromaDex Counsel, More

    Aug 08 2024 
    • By Malcolm Spicer

    Avista VC acquires OTC CMO Trillium; FDA deputy commissioner Jones to open CRN conference; AG1 founder steps down, COO moves up to CEO; ChromaDex hires general counsel; Ajinomoto, Shiru partner to develop sweet proteins; and change at ingredient provider LBB helm.

  • FSMA Facility, Recall Reinspection Fees Remain On Ice As FDA Heats Up Making Program ‘Feasible’

    FSMA Facility, Recall Reinspection Fees Remain On Ice As FDA Heats Up Making Program ‘Feasible’

    Aug 07 2024 
    • By Malcolm Spicer

    As it has every year since FSMA was passed in 2011, FDA doesn’t plan to impose reinspection fees until it publishes guidance for small businesses to request reductions. FY2025 budget proposal includes plan “to re-structure the fee programs to make it more administratively feasible to operate.”

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • HBW Perspectives
  • Interviews
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window